ArticleCureus2026
Using Large Language Models to Predict Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Proof-of-Concept Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition linked to type 2 diabetes and other metabolic risk factors. Timely detection of advanced fibrosis (≥F3) in MASLD patients is critical for effective clinical management. Traditional risk scores, such as the Fibrosis-4 Index (FIB-4) and NAFLD Fibrosis Score (NFS), have limitations, prompting the exploration of machine learning models for improved risk prediction.
objectivesThis proof-of-concept study evaluates the feasibility of using large language models (LLMs), specifically GPT-4 and GPT-3.5 (OpenAI, Inc., San Francisco, United States), to predict advanced liver fibrosis in individuals with MASLD using only structured clinical variables from the National Health and Nutrition Examination Survey (NHANES).
methodsWe used NHANES 2017-2020 data, including 162 participants with MASLD. GPT-4 and GPT-3.5 were accessed via application programming interface (API) to predict fibrosis risk using variables such as age, BMI, aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, and HbA1c. Performance was evaluated using sensitivity, specificity, area under the receiver operating characteristic curve (AUROC), and Brier score, with model thresholds set at 40.5% for GPT-4 and 45% for GPT-3.5 based on Youden's index.
resultsGPT-4 achieved an AUROC of 0.91 (95% CI: 0.86-0.96), while GPT-3.5 demonstrated an AUROC of 0.90 (95% CI: 0.85-0.95). Both models showed strong calibration, with GPT-4 maintaining superior specificity (0.86 vs. 0.82). The models' performance outpaced traditional risk scores, such as FIB-4.
conclusionsGPT-based LLMs show strong potential for predicting advanced fibrosis in MASLD, offering a scalable, interpretable tool for clinical use. Further validation across diverse populations and clinical settings is needed to confirm generalizability and refine the approach before clinical adoption.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.